Shilpa Medicare rallies af | Detailed News | 1336024/25
  • BUSINESS ENQUIRY : +91 80122 78000
      CUSTOMER SUPPORT : 044 4032 9999
  • BUSINESS ENQUIRY : +91 80122 78000   CUSTOMER SUPPORT : 044 4032 9999
YOU ARE ON THE NEW Goodwill WEBSITE, ACCESS THE OLD WEBSITE Click Here
07-Jul-2022 EOD 15 mins delay  NIFTY  16,132.90  [143.10]commodity-trading-and-shares-brokers-in-indiaAdani-Ports  703.60   [1.33]   |   Apollo-Hospitals  3915.25   [0.82]   |   Asian-Paints  2891.40   [1.05]   |   Axis-Bank  658.15   [0.03]   |   B-P-C-L  329.40   [2.52]   |   Bajaj-Auto  3795.50   [0.60]   |   Bajaj-Finance  5860.70   [-0.95]   |   Bajaj-Finserv  11967.35   [-0.51]   |   Bharti-Airtel  686.80   [-1.03]   |   Britannia-Inds  3810.25   [-0.54]   |   Cipla  935.25   [-1.09]   |   Coal-India  186.00   [2.37]   |   Divi's-Lab  3656.40   [0.32]   |   Dr-Reddy's-Labs  4336.45   [-1.22]   |   Eicher-Motors  2944.20   [1.25]   |   Grasim-Inds  1374.85   [0.38]   |   H-D-F-C  2245.55   [0.72]   |   HCL-Technologies  989.85   [0.33]   |   HDFC-Bank  1395.80   [1.79]   |   HDFC-Life-Insur  554.60   [-0.51]   |   Hero-Motocorp  2839.45   [0.27]   |   Hind-Unilever  2472.95   [-1.02]   |   Hindalco-Inds  361.65   [6.07]   |   ICICI-Bank  742.00   [2.21]   |   IndusInd-Bank  861.00   [2.92]   |   Infosys  1498.70   [0.47]   |   ITC  291.95   [0.92]   |   JSW-Steel  574.60   [3.62]   |   Kotak-Mah-Bank  1738.50   [1.99]   |   Larsen-and-Toubro  1611.10   [3.53]   |   M-and-M  1133.30   [2.60]   |   Maruti-Suzuki  8606.40   [-0.27]   |   Nestle-India  18204.95   [-1.00]   |   NTPC  140.45   [1.08]   |   O-N-G-C  123.50   [2.11]   |   Power-Grid-Corpn  212.55   [1.00]   |   Reliance-Industr  2388.10   [-0.98]   |   SBI-Life-Insuran  1124.60   [0.76]   |   Shree-Cement  20014.60   [0.12]   |   St-Bk-of-India  486.75   [1.42]   |   Sun-PharmaInds  849.45   [1.40]   |   Tata-Consumer  754.85   [0.65]   |   Tata-Motors  430.85   [3.48]   |   Tata-Steel  900.00   [4.88]   |   TCS  3287.85   [0.83]   |   Tech-Mahindra  1020.75   [1.07]   |   Titan-Company  2127.50   [5.66]   |   UltraTech-Cem  5838.85   [0.19]   |   UPL  682.75   [3.06]   |   Wipro  420.80   [1.14]   |   
USEFUL
LINKS

DetailedNews

Shilpa Medicare rallies after robust Q4 results Back
24-May-22   12:23 Hrs IST
Profit before tax (PBT) soared 452.4% to Rs 46.40 crore in Q4 FY22 over Q4 FY21. EBITDA surged 139% to Rs 79.2 crore in Q4 FY22 from Rs 33.1 crore registered in Q4 FY21. EBITDA margin improved to 23% in Q4 FY22 from 15% in Q4 FY21.

Total expenses were up by 47.1% year on year to Rs 267.99 crore in the quarter ended 31 March 2022. The cost of raw materials increased 50.7% year on year to Rs 94.38 crore in Q4 FY22.

On full year basis, the pharma company reported a 59% decline in net profit to Rs 60.66 crore despite of a 27.1% rise in net sales to Rs 1,145.52 crore in the financial year ended 31 March 2022 over the financial year ended 31 March 2021.

Commenting on the performance, Vishnukant Bhutada, managing director of Shilpa Medicare said, “The healthy momentum of sales continues to build on the back of growth in commercially launched products in key markets. The Formulations segment is recording traction in ex-US markets including across the EU, India and RoW. We have an attractive portfolio of products lined up for launch that will support this growth. The declining share of CRAMS will proportionately support margin momentum through expansion in product sales.

Commenting on unlocking value, Bhutada said, “I am pleased to announce that the Board has agreed to initiate IPO process of Shilpa Pharma Lifesciences to unlock value of the API business and provide the requisite impetus for its growth. Additional costs towards the remedial measures for the formulations plant are impacting the margins.”

He lastly added, “The prevailing inflationary trends are proving to be a challenge and our effort has been to improve efficiencies in the operation in order to mitigate them. Additional costs towards the remedial measures for the Formulations plant are impacting the margins. As the product mix improves in favour of the Formulation business and thenewer initiatives of API segment, we shall see a strong underlying build up in the profile of margins going forward. We are moving ahead with plans for biologicals with 3 products at clinical phase and tapping a very attractive segment in the market, with limited competition andgood potential to grow. The Company is prioritizing development of world-class, new products in multiple segments, which upon launch is likely to result in a superiorbusiness and earnings profile.”

The company's board recommended a dividend of Rs 1.10 per equity share for the financial year ended 31 March 2022.

Shilpa Medicare is a global brand in manufacturing and supplying of affordable API and formulation globally in different regulated markets.

Powered by Capital Market - Live News

Attention Investor
KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc), you need not undergo the same process again when you approach another intermediary. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account. Prevent Unauthorized Transactions in your Demat account\Trading account: Update your Mobile Number with your Depository Participant\Exchange. Receive alerts on your Registered Mobile for all debit and other important transactions in your Demat account\Trading account directly from Depository\Exchange on the same day.........issued in the interest of investors.
The Stock Exchange, Mumbai is not in any manner answerable, responsible or liable to any person or persons for any acts of omission or commission, errors, mistakes and/or violation, actual or perceived, by us or our partners, agents, associates etc., of any of the Rules, Regulations, Bye-laws of the Stock Exchange, Mumbai, SEBI Act or any other laws in force from time to time. The Stock Exchange, Mumbai is not answerable, responsible or liable for any information on this Website or for any services rendered by our employees, our servants, and us.
Please DO NOT disclose your User ID and/or Passwords to any person, even Goodwill staff never ask you to share the same. Goodwill is NEITHER liable for any loss arising from your sharing of your password with anyone, NOR from its consequent unauthorized use.